home icon

News

August 8, 2018

Nativis Appoints Andrew Daniels to Board of Directors

Read More

July 5, 2018

Nativis Research Partner Presents at the International Symposium on Pediatric Neuro-Oncology Annual Meeting in Denver

Read More

April 18, 2018

FDA Grants Third Humanitarian Use Device Designation for Nativis Voyager® Pediatric System

Read More

April 5, 2018

FDA Grants Humanitarian Use Designation for Nativis Voyager® Pediatric System In Medulloblastoma

Read More

March 22, 2018

Nativis to Present at 17th Annual Needham & Co. Healthcare Conference

Read More

February 20, 2018

FDA Grants Humanitarian Use Designation for Nativis Voyager® Pediatric System

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

November 7, 2017

Nativis Research Partners to Present at the Society for Neuro-Oncology Annual Meeting in San Francisco

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

October 23, 2017

CEO Chris Rivera details Nativis’ successes and future goals

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

October 17, 2017

Nativis Research Partner to Present at COGNO Conference in Australia

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

October 3, 2017

Nativis Announces Engagement of Strategic Financial Advisory Firm Outcome Capital, LLC

Read More
Older » « Newer

EMulate Therapeutics Voyager® ulRFE® System for rGBM is an investigational medical device. Limited by United States law to investigational use only.

© EMulate Therapeutics 2019. All rights reserved.